Muhammed YAYLA, Damla ÇETİN, SEFER ÜSTEBAY, Hayrunisa BEKİS BOZKURT, Ömer ERTEKİN, Döndü Ülker ÜSTEBAY

Boy kısalığı olan çocukların serum ürotensin 2 düzeylerinin igf-1 ile ilişkisi

Amaç: Çalışmamızda boy kısalığı olan çocuklardaki Ürotensin 2’nin serum düzeylerini araştırarak İGF-1 ve İGFBP-3 gibi büyümeden sorumlu olan endojen maddeler arasındaki korelasyonu değerlendirmeyi amaçladık. Gereç ve Yöntem: Çalışmamızda 150 hasta ve 30 sağlıklı çocuk değerlendirmeye alındı. Bunlar kontrol, ailevi boy kısalığı, yapısal boy kısalığı, malnütrisyon ve çölyak olacak şekilde 5 gruba ayrıldı. Bunlarda kendi içinde İGF-1 ve İGFBP-3 düzeyleri düşük yada normal olacak şekilde gruplandırıldı. Bulgular: İGF-1 düzeyi normal olan ailevi boy kısalığı olan çocukların, düşük İGF-1 düzeyi olan yapısal boy kısalığı, malnütrisyonlu ve çölyak grubundaki çocukların serum Ürotensin 2 düzeyleri kontrol grubuna göre yüksek bulunmuştur. İGFBP-3 düzeylerine göre ise tüm gruplarda Ürotensin 2 düzeyi kontrole göre yüksek bulunmuştur. Sonuç: Çalışmamızda Ürotensin 2’nin çocuklarda büyüme gelişme geriliği ve boy kısalığı fizyopatolojisinderol alabileceği düşünülmektedir.

Objective: In this study, we aimed to evaluate the correlation between endogenous substances responsible for growth such as IGF-1 and IGFBP-3 by investigating serum levels of Urotensin 2 in children with short stature. Material and Methods: In this study, 150 patients (short stature) and 30 healthy children were evaluated. These were divided into 5 groups, including control, family short stature, structural short stature, malnutrition and celiac disease.The IGF-1 and IGFBP-3 levels were determined as low or normal in these groups. Results: Serum Urotensin 2 levels were found to be higher in structural short stature, malnutrition and celiac disease with low IGF-1 levels and familial short stature with normal IGF-1 levels than control. According to IGFBP-3 levels, Urotensin2 levels were higher in all groups compared to control. Conclusion: In our study, Urotensin 2 may play a role in the pathophysiology of growth retardation and shortening in children.

PDF

___

1. Ranke MB, Wit JM. Growth hormone - past, present and future. Nat Rev Endocrinol 2018;14:285-300.

2. Wang B, Qin C, Zhang C, et al. Differential involvement of signaling pathways in the regulation of growth hormone release by somatostatin and growth hormone-releasing hormone in orange-spotted grouper (Epinephelus coioides). Mol Cell Endocrinol 2014;382:851-9.

3. Chinoy A, Murray PG. Diagnosis of growth hormone deficiency in the paediatric and transitional age. Best Pract Res Clin Endocrinol Metab 2016;30:737-47.

4. Wong SC, Dobie R, Altowati MA, et al. Growth and the Growth Hormone-Insulin Like Growth Factor 1 Axis in Children With Chronic Inflammation: Current Evidence, Gaps in Knowledge, and Future Directions. Endocr Rev 2016;37:62-110.

5. Murray PG, Clayton PE, Chernausek SD. A genetic approach to evaluation of short stature of undetermined cause. Lancet Diabetes Endocrinol 2018;6:564-74.

6. Boucher J, Softic S, El Ouaamari A, et al. Differential Roles of Insulin and IGF-1 Receptors in Adipose Tissue Develop-

7. Soni H, Adebiyi A. Urotensin II-induced store-operated Ca(2+) entry contributes to glomerular mesangial cell proliferation and extracellular matrix protein production under high glucose conditions. Sci Rep 2017;7:18049.

8. Matsumoto T, Watanabe S, Kobayashi S, et al. Age-Related Reduction of Contractile Responses to Urotensin II Is Seen in Aortas from Wistar Rats but Not from Type 2 Diabetic Goto-Kakizaki Rats. Rejuvenation Res 2017;20:134-45.

9. Cadirci E, Halici Z, Yayla M, et al. Blocking of urotensin receptors as new target for treatment of carrageenan induced inflammation in rats. Peptides 2016;82:35-43.

10. Satiroglu O, Durakoglugil ME, Cetin M, et al. The role of urotensin II and atherosclerotic risk factors in patients with slow coronary flow. Interv Med Appl Sci 2016;8:158-63.

11. Malagon MM, Molina M, Gahete MD, et al. Urotensin II and urotensin II-related peptide activate somatostatin receptor subtypes 2 and 5. Peptides 2008;29:711-20.

12. Rivas RJ, Nishioka RS, Bern HA. In vitro effects of somatostatin and urotensin II on prolactin and growth hormone secretion in tilapia, Oreochromis mossambicus. Gen Comp Endocrinol 1986;63:245-51.

13. Sun C, Duan D, Li B, et al. UII and UT in grouper: cloning and effects on the transcription of hormones related to growth control. J Endocrinol 2014;220:35-48.

14. Argente J, Luis AP-J. Genetic causes of proportionate short stature. Best Pract Res Clin Endocrinol Metab 2018;32:499- 522.

15. Gönç EN, Özön ZA, Alikaşifoğlu A, Kandemir N. Çocuklarda büyümenin değerlendirilmesi ve boy kısalığında tanısal yaklaşım Çoc Sağ ve Hast Derg 2015;58:85.

16. Ashpole NM, Sanders JE, Hodges EL, Yan H, Sonntag WE. Growth hormone, insulin-like growth factor-1 and the aging brain. Exp Gerontol 2015;68:76-81.

17. Ross B, McKendy K, Giaid A. Role of urotensin II in health and disease. Am J Physiol Regul Integr Comp Physiol 2010;298:1156-72.

18. Palabiyik SS, Karakus E, Akpinar E, et al. The Role of Urotensin Receptors in the Paracetamol-Induced Hepatotoxicity Model in Mice: Ameliorative Potential of Urotensin II Antagonist. Basic Clin Pharmacol Toxicol 2016;118:150-69.

19. Tostivint H, Ocampo D, Bergqvist CA, et al. Molecular evolution of GPCRs: Somatostatin/urotensin II receptors. J Mol Endocrinol 2014;52:61-86.

20. Liu Y, Lu D, Zhang Y, et al. The evolution of somatostatin in vertebrates. Gene 2010;463:21-8.

21. Tostivint H, Quan FB, Bougerol M, Kenigfest NB, Lihrmann I. Impact of gene/genome duplications on the evolution of the urotensin II and somatostatin families. Gen Comp Endocrinol 2013;188:110-7.

22. Huitron-Resendiz S, Kristensen MP, Sanchez-Alavez M, et al. Urotensin II modulates rapid eye movement sleep through activation of brainstem cholinergic neurons. J Neurosci 2005;25:5465-74.

23. Kim TW, Jeong JH, Hong SC. The impact of sleep and circadian disturbance on hormones and metabolism. Int J Endocrinol 2015;15:5917-29.

24. Vaudry H, Leprince J, Chatenet D, et al. International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, urotensin II-related peptide, and their receptor: from structure to function. Pharmacol Rev 2015;67:214-58.

25. Bucharles C, Bizet P, Arthaud S, et al. Concordant localization of functional urotensin II and urotensin II-related peptide binding sites in the rat brain: Atypical occurrence close to the fourth ventricle. J Comp Neurol 2014;522:2634-49.

26. Quan FB, Dubessy C, Galant S, et al. Comparative distribution and in vitro activities of the urotensin II-related peptides URP1 and URP2 in zebrafish: evidence for their colocalization in spinal cerebrospinal fluid-contacting neurons. PLoS One 2015;10:1192-90.

27. Yasuda T, Masaki T, Gotoh K, et al. Intracerebroventricular administration of urotensin II regulates food intake and sympathetic nerve activity in brown adipose tissue. Peptides 2012;35:131-5.

28. Cederholm T, Barazzoni R, Austin P, et al. ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr 2017;36:49-64.

29. Guerra RS, Fonseca I, Sousa AS, et al. ESPEN diagnostic criteria for malnutrition - A validation study in hospitalized patients. Clin Nutr 2017;36:1326-32.

30. Güleç SG UN, Polat S, Yağar G, Hatipoğlu N,. Hastanede yatan üç yaş altı çocuklarda malnütrisyon durumunun değerlendirilmesi. Şişli Etfal Hastanesi Tıp Bülteni 2011;45:124-29.

31. Serin Y, Akbulut G. Celiac Disease and the Contemporary Approach to Gluten-Free Diet Treatment. Turkiye Klinikleri J Health Sci 2017;2:192-200.

32. Soylu ÖB, Ecevit ÖÇ. Çölyak hastalığı tanısı ile izlenen olguların klinik değerlendirmesi. İzmir Dr Behçet Uz Çocuk Hast Dergisi 2013;3:38-43.

33. Kuloglu Z. Celiac Disease. Turkish J Pediatr Dis 2014;2:105- 11.

34. Demirçeken FG. Gluten enteropatisi (çölyak hastalığı): Klasik bir öykü ve güncel gelişmeler. Günc gastroenterol 2011;15:58-72.

35. Rubio-Tapia A, Hill ID, Kelly CP, et al. ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol 2013;108:656-76.